Imagine facing stage III colon cancer, a tough battle where every month counts. Standard treatment often includes a combination of chemotherapy drugs, but for some patients, this isn't enough. In a recent study, researchers looked at whether adding a new drug called atezolizumab could improve the chances of staying cancer-free after treatment. They found that patients who received atezolizumab alongside standard chemotherapy had an impressive 86% chance of being disease-free after three years, compared to just 76% for those who only received chemotherapy. While this sounds promising, it’s important to note that more patients experienced serious side effects with the new treatment. This means that while the new combination could lead to better survival rates, it also comes with increased risks. As researchers continue to explore this treatment, patients can feel hopeful about new options that may improve their fight against colon cancer.
Could a New Treatment Boost Survival for Stage III Colon Cancer Patients?
Plain Language Summary
What this means for you:
A new treatment could significantly improve survival rates for patients with stage III colon cancer, offering hope for better outcomes. What this means for you:
A new treatment could significantly improve survival rates for patients with stage III colon cancer, offering hope for better outcomes. View Original Abstract ↓
BACKGROUND: Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen. Whether the addition of atezolizumab (an anti-programmed death ligand 1 agent) to a modified FOLFOX6 regimen (fluorouracil, oxaliplatin, and leucovorin; called mFOLFOX6) would improve outcomes in patients with stage III colon cancer with mismatch repair-deficient (dMMR) status is unclear.
METHODS: In a phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with resected stage III dMMR tumors to receive either adjuvant atezolizumab plus mFOLFOX6 for 6 months, with atezolizumab continued as monotherapy (for a total of 12 months of therapy), or mFOLFOX6 alone for 6 months. The primary end point was disease-free survival. Secondary end points were overall survival and the adverse-event profile.
RESULTS: A total of 355 patients were assigned to receive atezolizumab plus mFOLFOX6 and 357 to receive mFOLFOX6 alone. The median age of the patients was 64 years, 55.1% were women, and 53.9% had tumors that were T4, N2, or both (indicating high risk). At a median follow-up of 40.9 months, the 3-year disease-free survival was 86.3% (95% confidence interval [CI], 81.8 to 89.8) in the atezolizumab-mFOLFOX6 group, as compared with 76.2% (95% CI, 70.9 to 80.6) in the mFOLFOX6 group (hazard ratio for disease recurrence or death, 0.50; 95% CI, 0.35 to 0.73; P<0.001). Adverse events of grade 3 or 4 occurred in 84.1% of the patients who received atezolizumab plus mFOLFOX6 and in 71.9% of those who received mFOLFOX6 alone.
CONCLUSIONS: The addition of atezolizumab to mFOLFOX6 significantly improved disease-free survival among patients with stage III dMMR colon cancer. (Funded by the National Cancer Institute of the National Institutes of Health and Genentech; ATOMIC ClinicalTrials.gov number, NCT02912559.).